Could a new drug help fight a rare thymus cancer?
NCT ID NCT06980077
First seen Jun 25, 2026 · Last updated Jul 08, 2026 · Updated 4 times
Summary
This phase II trial is testing a drug called ivonescimab in 25 people with thymic carcinoma, a rare cancer of the thymus gland that has already been treated. Ivonescimab is an immunotherapy that helps the body's immune system recognize and attack cancer cells. The main goal is to see if the drug can shrink tumors, and researchers will also track how long any response lasts and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ivonescimab (a type of immunotherapy that helps the immune system attack cancer cells)
- What this could lead to
- If successful, this could provide a new treatment option for people with thymic carcinoma that has not responded to prior therapies.
- What could go wrong
- This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects like immune-related inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMUS CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
NOT_YET_RECRUITINGBoston, Massachusetts, 02115, United States
-
UCLA / Jonsson Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90095, United States
-
University of California at Davis (UCD)
NOT_YET_RECRUITINGDavis, California, 95817, United States
-
University of California at Irvine (UCI)
NOT_YET_RECRUITINGIrvine, California, 92868, United States
-
University of California at San Francisco (UCSF)
RECRUITINGSan Francisco, California, 94115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.